上海凱寶(300039.SZ):與盈科瑞創新藥物研究就YKRH00020霧化吸入溶液項目合作開發簽訂合同
格隆匯8月15日丨上海凱寶(300039.SZ)公佈,公司作為甲方,與北京盈科瑞創新藥物研究有限公司(“盈科瑞創新藥物研究”、“乙方”)就YKRH00020霧化吸入溶液項目合作開發簽訂合同。
盈科瑞創新藥物研究是北京盈科瑞創新醫藥股份有限公司的控股子公司,公司獨立董事葉祖光的直系親屬擔任北京盈科瑞創新醫藥股份有限公司董事,根據《深圳證券交易所創業板股票上市規則》等相關規定,盈科瑞創新藥物研究為公司關聯法人,此次交易構成關聯交易。
YKRH00020霧化吸入溶液項目為盈科瑞創新藥物研究在研的臨牀前研究項目,目前已完成YKRH00020成藥性研究,過敏性、刺激性預試驗,藥效研究,藥代研究並中試生產一批。已提交專利申請。
盈科瑞創新藥物研究擁有完整的霧化吸入製劑臨牀前研發技術平台(包括藥學、藥理、藥代、安評等)和霧化吸入製劑在研新藥,此次合同的簽訂,有利於促進各方技術、產品與服務的延伸和發展,提升公司的抗風險能力,促進公司長遠發展。
合同涉及的項目是主要用於兒童和老年患者給藥的呼吸疾病類霧化吸入製劑項目,與公司儲備新藥的戰略研發方向一致,為公司在呼吸領域的深度發展奠定基礎。經過多方考察研究,公司決定與盈科瑞創新藥物研究就該項目進行合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.